Skip to main content
. 2019 Jan 8;2019(1):CD006404. doi: 10.1002/14651858.CD006404.pub3

Sagara 2018 (Bobo‐Doiulasso, Burkina Faso).

Methods RCT* ‐ represents disaggregated data from Sagara 2018 (see above)
Participants Number receiving at least one study treatment: 232
Interventions
  • Pyronaridine‐artesunate (n = 212)

  • Artemether‐lumefantrine (n = 220)

Outcomes
Notes Location: Bobo, Burkina Faso
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Represents disaggregated data from Sagara 2018 (see above)
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection bias) 
 All outcomes Low risk
Incomplete outcome data (attrition bias) 
 All outcomes Low risk
Selective reporting (reporting bias) Low risk
Other bias Low risk
Adverse event monitoring (detection bias) 
 Adverse Events Low risk
Incomplete adverse event reporting (reporting bias) 
 Adverse events Low risk